Lipoprotein(a) was a key focus. First, the 2018 US Cholesterol Guidelines incorporated elevated lipoprotein(a) as a marker of cardiovascular risk. Second, a Latebreaker session showed a favourable benefit versus risk profile for a novel antisense oligonucleotide specific to the apolipoprotein(a) component of lipoprotein(a).
Now the stage is truly set to test the ‘lipoprotein(a) hypothesis’ with a phase III trial to evaluate whether lowering elevated lipoprotein(a) levels reduces cardiovascular events.
Latest videos
Frederick J. Raal
Lerodalcibep: What does LIBerate-HeFH tell us?
Steve Humphries
Verve-101: Where are we up to with PCSK9 gene editing?
Marianna Pavlyha
Apo(a) size and PAD revascularisation outcomes: What’s the link?
Steve Nissen
Lepodisiran: What progress towards Lp(a) reduction?
« Back to videos
